Acorda Therapeutics, Inc. (ACOR) has an overall financial health rating of B with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-04-11.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-04-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-08 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-28 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
